NeoGenomics Company Profile (NASDAQ:NEO)

About NeoGenomics (NASDAQ:NEO)

NeoGenomics logoNeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEO
  • CUSIP: N/A
  • Web: www.neogenomics.com
Capitalization:
  • Market Cap: $584.77 million
  • Outstanding Shares: 79,237,000
Average Prices:
  • 50 Day Moving Avg: $7.75
  • 200 Day Moving Avg: $8.28
  • 52 Week Range: $6.90 - $9.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 26.36
  • P/E Growth: 2.10
Sales & Book Value:
  • Annual Revenue: $246.06 million
  • Price / Sales: 2.38
  • Book Value: $2.13 per share
  • Price / Book: 3.46
Profitability:
  • EBIDTA: $27.3 million
  • Net Margins: -3.10%
  • Return on Equity: 3.56%
  • Return on Assets: 2.05%
Debt:
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 2.62%
  • Quick Ratio: 2.45%
Misc:
  • Average Volume: 371,016 shs.
  • Beta: 0.92
  • Short Ratio: 22.27
 

Frequently Asked Questions for NeoGenomics (NASDAQ:NEO)

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings data on Wednesday, April, 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.02. The firm had revenue of $61.68 million for the quarter, compared to the consensus estimate of $61.26 million. NeoGenomics had a negative net margin of 3.10% and a positive return on equity of 3.56%. The company's revenue for the quarter was up 3.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.03 earnings per share. View NeoGenomics' Earnings History.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY17 earnings guidance on Wednesday, April, 26th. The company provided earnings per share guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.19. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $264.60 million.NeoGenomics also updated its Q2 guidance to $0.03-0.04 EPS.

Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?

7 brokers have issued 12-month price objectives for NeoGenomics' stock. Their forecasts range from $10.00 to $12.00. On average, they anticipate NeoGenomics' stock price to reach $11.00 in the next year. View Analyst Ratings for NeoGenomics.

What are analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:

  • 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (5/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:

  • Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
  • George A. Cardoza, Chief Financial Officer
  • Robert J. Shovlin, Chief Operating Officer
  • Steven C. Jones, Executive Vice President - Finance, Chief Compliance Officer, Director
  • Edwin F. Weidig III, CPA, Principal Accounting Officer, Vice President - Finance
  • Steven A. Ross, Chief Information Officer
  • Steven G. Brodie Ph.d., Vice President - Operations
  • Jennifer Balliet, Vice President - Human Resources
  • Sally Agersborg M.D. Ph.D., Director of Hematopathology and Medical Director
  • Maher Albitar M.D., Chief Medical Officer, Director - Research and Development

Who owns NeoGenomics stock?

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.41%), Artisan Partners Limited Partnership (3.12%), Next Century Growth Investors LLC (2.65%), RMB Capital Management LLC (2.15%), Janus Capital Management LLC (2.12%) and Driehaus Capital Management LLC (1.80%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Who sold NeoGenomics stock? Who is selling NeoGenomics stock?

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Next Century Growth Investors LLC, Driehaus Capital Management LLC, Russell Investments Group Ltd., Summit Creek Advisors LLC, RMB Capital Management LLC, Millrace Asset Group Inc. and Artisan Partners Limited Partnership. Company insiders that have sold NeoGenomics stock in the last year include Maher Albitar and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

Who bought NeoGenomics stock? Who is buying NeoGenomics stock?

NeoGenomics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Gabelli Funds LLC, IronBridge Capital Management LP, Renaissance Technologies LLC, Emerald Advisers Inc. PA, Dimensional Fund Advisors LP, Cowen Prime Services LLC and Northpointe Capital LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin. View Insider Buying and Selling for NeoGenomics.

How do I buy NeoGenomics stock?

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NeoGenomics stock can currently be purchased for approximately $7.38.


MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  210
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeoGenomics (NASDAQ:NEO) (?)
Ratings Breakdown: 1 Sell Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $11.00 (49.05% upside)

Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/28/2017BTIG ResearchReiterated RatingBuy$11.00N/AView Rating Details
5/27/2017Cantor FitzgeraldSet Price TargetBuy$11.00N/AView Rating Details
11/16/2016Axiom SecuritiesReiterated RatingHold -> SellN/AView Rating Details
10/3/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
9/8/2016Raymond James Financial, Inc.Initiated CoverageOutperform$10.00N/AView Rating Details
7/27/2016Benchmark Co.Boost Price TargetBuy$10.00 -> $12.00N/AView Rating Details
7/9/2016Craig HallumReiterated RatingBuyN/AView Rating Details
5/11/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
1/7/2016Janney Montgomery ScottInitiated CoverageBuy$11.00N/AView Rating Details
10/26/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for NeoGenomics (NASDAQ:NEO)
Earnings by Quarter for NeoGenomics (NASDAQ:NEO)
Earnings History by Quarter for NeoGenomics (NASDAQ:NEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017$0.01$0.03$61.26 million$61.68 millionViewN/AView Earnings Details
2/22/2017Q416$0.03$0.05$61.83 million$60.50 millionViewListenView Earnings Details
10/26/2016Q316$0.03$0.04$61.00 million$60.76 millionViewListenView Earnings Details
7/26/2016Q216$0.03$0.04$61.07 million$63.10 millionViewListenView Earnings Details
4/27/2016Q116($0.07)$0.03$57.00 million$59.70 millionViewListenView Earnings Details
3/1/2016Q415$0.02($0.03)$26.46 million$27.30 millionViewN/AView Earnings Details
4/28/2015Q115($0.02)($0.01)$23.36 million$23.00 millionViewN/AView Earnings Details
2/24/2015Q414$0.01$0.02$24.30 million$25.00 millionViewN/AView Earnings Details
10/30/2014Q314($0.01)$0.01$22.43 million$23.20 millionViewN/AView Earnings Details
7/17/2014Q214$0.01$0.01$19.84 million$20.70 millionViewN/AView Earnings Details
2/19/2014Q413$0.02$0.04$17.80 million$18.30 millionViewN/AView Earnings Details
10/23/2013Q313$0.01$0.02$16.84 million$16.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.01$16.20 million$15.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NeoGenomics (NASDAQ:NEO)
Current Year EPS Consensus Estimate: $0.18 EPS
Next Year EPS Consensus Estimate: $0.28 EPS

Dividends

Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NeoGenomics (NASDAQ:NEO)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 79.69%
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Steven G BrodieInsiderSell50,000$7.93$396,500.00View SEC Filing  
9/23/2016Maher AlbitarInsiderSell2,800$8.40$23,520.00View SEC Filing  
9/20/2016Maher AlbitarInsiderSell105,300$8.20$863,460.00View SEC Filing  
9/12/2016Maher AlbitarInsiderSell60,075$8.23$494,417.25View SEC Filing  
8/19/2016Maher AlbitarInsiderSell370,000$8.23$3,045,100.00View SEC Filing  
5/27/2016Oort Douglas M VanCEOSell481,387$8.73$4,202,508.51View SEC Filing  
5/18/2016Steven A RossInsiderSell18,000$8.50$153,000.00View SEC Filing  
5/9/2016Steven A RossInsiderSell15,000$8.22$123,300.00View SEC Filing  
5/2/2016Steven C JonesVPSell177,745$8.21$1,459,286.45View SEC Filing  
4/29/2016Steven A RossInsiderSell112,500$8.11$912,375.00View SEC Filing  
3/11/2016George CardozaCFOSell32,000$6.83$218,560.00View SEC Filing  
3/9/2016Oort Douglas M VanCEOSell450,000$7.10$3,195,000.00View SEC Filing  
3/3/2016Alison L HannahDirectorBuy10,000$6.90$69,000.00View SEC Filing  
12/7/2015Lynn A TetraultDirectorBuy3,500$7.72$27,020.00View SEC Filing  
12/3/2015Robert J ShovlinCOOBuy6,550$7.75$50,762.50View SEC Filing  
11/27/2015Steven C JonesVPSell385,000$8.09$3,114,650.00View SEC Filing  
11/2/2015Bruce K CrowtherDirectorBuy6,400$7.81$49,984.00View SEC Filing  
12/19/2014Robert H HorelVPSell32,389$4.21$136,357.69View SEC Filing  
12/18/2014Robert H HorelVPSell62,893$4.20$264,150.60View SEC Filing  
12/4/2014Michael T DentDirectorSell11,800$4.50$53,100.00View SEC Filing  
11/26/2014George CardozaCFOSell60,000$4.28$256,800.00View SEC Filing  
11/21/2014Michael T DentDirectorSell33,200$4.51$149,732.00View SEC Filing  
5/22/2014Robert P GaspariniInsiderSell100,000$3.49$349,000.00View SEC Filing  
5/19/2014Robert GaspariniInsiderSell10,000$3.65$36,500.00View SEC Filing  
3/28/2014Maher AlbitarInsiderBuy14,492$3.51$50,866.92View SEC Filing  
3/5/2014Michael T DentDirectorSell300,000$3.00$900,000.00View SEC Filing  
12/11/2013Robert P GaspariniInsiderSell20,100$3.70$74,370.00View SEC Filing  
12/9/2013George CardozaCFOSell20,000$3.66$73,200.00View SEC Filing  
12/5/2013Robert P GaspariniInsiderSell32,996$3.67$121,095.32View SEC Filing  
12/3/2013Robert P GaspariniInsiderSell32,146$3.67$117,975.82View SEC Filing  
11/25/2013Steven C JonesVPSell112,969$3.58$404,429.02View SEC Filing  
4/30/2013Steven C JonesDirectorSell100,000$3.71$371,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NeoGenomics (NASDAQ:NEO)
Latest Headlines for NeoGenomics (NASDAQ:NEO)
Source:
DateHeadline
americanbankingnews.com logoBTIG Research Reiterates "Buy" Rating for NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - May 28 at 7:20 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Given a $11.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 27 at 9:34 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 11:06 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.02 Per Share
www.americanbankingnews.com - May 17 at 4:16 PM
finance.yahoo.com logoNeoGenomics Reports that its NeoLAB(R) Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer
finance.yahoo.com - May 15 at 10:13 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:14 AM
americanbankingnews.com logoNeoGenomics (NEO) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - May 4 at 1:21 AM
americanbankingnews.com logoNeoGenomics (NEO) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 3:27 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 28 at 8:00 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Expected to Post Quarterly Sales of $65.99 Million
www.americanbankingnews.com - April 28 at 1:16 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 28 at 1:04 AM
News IconBRIEF-NeoGenomics sees Q2 2017 adjusted earnings per share $0.03-$0.04
www.businessinsider.com - April 28 at 12:19 AM
americanbankingnews.com logoNeoGenomics (NEO) Receiving Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 10:00 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 27 at 2:54 PM
fool.com logoHere's Why NeoGenomics, Inc. Is Dropping Today - Motley Fool
www.fool.com - April 27 at 9:56 AM
finance.yahoo.com logoEdited Transcript of NEO earnings conference call or presentation 26-Apr-17 3:00pm GMT
finance.yahoo.com - April 27 at 9:56 AM
americanbankingnews.com logo Brokerages Anticipate NeoGenomics, Inc. (NEO) Will Post Earnings of $0.01 Per Share
www.americanbankingnews.com - April 27 at 1:11 AM
finance.yahoo.com logoNeoGenomics reports 1Q loss
finance.yahoo.com - April 26 at 11:29 PM
seekingalpha.com logoNeoGenomics revenues up 3% in Q1; revises 2017 guidance - Seeking Alpha
seekingalpha.com - April 26 at 6:28 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Posts Earnings Results, Meets Expectations
www.americanbankingnews.com - April 26 at 4:58 PM
fool.com logoHere's Why NeoGenomics, Inc. Is Dropping Today
www.fool.com - April 26 at 1:01 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Releases FY17 Earnings Guidance
www.americanbankingnews.com - April 26 at 10:12 AM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Issues Q2 Earnings Guidance
www.americanbankingnews.com - April 26 at 10:12 AM
americanbankingnews.com logoNeoGenomics' (NEO) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 26 at 9:57 AM
finance.yahoo.com logoETFs with exposure to NeoGenomics, Inc. : April 25, 2017
finance.yahoo.com - April 25 at 6:03 PM
finance.yahoo.com logoInvestor Network Invites You to the NeoGenomics First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, April 26, 2017
finance.yahoo.com - April 25 at 6:03 PM
americanbankingnews.com logoNeoGenomics (NEO) Getting Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 24 at 9:13 PM
americanbankingnews.com logoNeoGenomics (NEO) Getting Very Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 21 at 5:24 PM
finance.yahoo.com logoNeoGenomics Appoints Bill Bonello as Vice President, Treasurer ... - Yahoo Finance
finance.yahoo.com - April 20 at 9:35 AM
finance.yahoo.com logoNeoGenomics Appoints Bill Bonello as Vice President, Treasurer, and Director of Corporate Development
finance.yahoo.com - April 20 at 9:35 AM
finance.yahoo.com logoNeoGenomics, Inc. – Value Analysis (NASDAQ:NEO) : April 19, 2017
finance.yahoo.com - April 19 at 6:49 PM
americanbankingnews.com logoNeoGenomics (NEO) Given News Impact Score of 0.31
www.americanbankingnews.com - April 18 at 6:51 PM
finance.yahoo.com logoNeoGenomics, Inc. breached its 50 day moving average in a Bullish Manner : NEO-US : April 18, 2017
finance.yahoo.com - April 18 at 10:12 AM
americanbankingnews.com logoNeoGenomics (NEO) Receiving Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 15 at 12:57 PM
finance.yahoo.com logoNeoGenomics Schedules its Q1 2017 Earnings Release for April 26, 2017
finance.yahoo.com - April 14 at 6:29 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.01 Per Share
www.americanbankingnews.com - April 5 at 4:30 PM
americanbankingnews.com logoNeoGenomics, Inc. (NEO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 30 at 2:01 PM
americanbankingnews.com logoInsider Selling: NeoGenomics, Inc. (NEO) Insider Sells 50,000 Shares of Stock
www.americanbankingnews.com - March 22 at 7:44 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates "Overweight" Rating for NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - March 22 at 2:26 PM
finance.yahoo.com logoAnatomic Pathology Market Worth 21.9 Billion USD by 2021
finance.yahoo.com - March 21 at 11:34 AM
finance.yahoo.com logoNEOGENOMICS INC Financials
finance.yahoo.com - March 17 at 3:44 PM
finance.yahoo.com logoMoving Average Crossover Alert: NeoGenomics (NEO)
finance.yahoo.com - March 15 at 6:58 PM
businesswire.com logoNeoGenomics and Definiens Enter Into Agreement to Develop ... - Business Wire (press release)
www.businesswire.com - March 14 at 10:51 AM
biz.yahoo.com logoNEOGENOMICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 14 at 10:51 AM
streetinsider.com logoNeoGenomics (NEO), Definiens to Develop Novel Assays
www.streetinsider.com - March 13 at 10:09 AM
finance.yahoo.com logoNeoGenomics and Definiens Enter Into Agreement to Develop Novel Assays for Clinical Trials & Clinical Testing
finance.yahoo.com - March 13 at 10:09 AM
finanznachrichten.de logoClinical Laboratory Services Market 2015-2022 - Global Strategic Business Report 2017 - Research and Markets
www.finanznachrichten.de - March 3 at 11:49 PM
capitalcube.com logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017
us.rd.yahoo.com - February 23 at 11:50 PM
capitalcube.com logoNeoGenomics, Inc. :NEO-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017
us.rd.yahoo.com - February 23 at 11:50 PM
finance.yahoo.com logoEdited Transcript of NEO earnings conference call or presentation 22-Feb-17 4:00pm GMT
finance.yahoo.com - February 23 at 12:27 AM

Social

Chart

NeoGenomics (NEO) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff